Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor

(Yates Public Relations) Aileron Therapeutics announced today that its collaborators, James E. Bradner, M.D., of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, Ph.D., Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex” showing that stapled peptides can potently and directly inhibit the transcription factor Notch1. This validates the potential for Stapled Peptides to modulate previously untargetable intracellular biological targets.

source : www.eurekalert.org

Related News:

• Stanford Study: What Makes You Unique? Not Genes So Much As Surrounding Sequences
• Hutterite study: Vaccinating kids for flu may help prevent transmission, protect those who are not vaccinated
• Researchers Develop Tool To Help Study Prostate Cancer
• Hospice Study Finds Racial Disparities (CME/CE)
• Shoulder Function Not Fully Restored After Surgery: Henry Ford Hospital Study
• Hospice Study Finds Racial Disparities
• Phase III REGION-I Study Shows PEP005 (ingenol Mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions In Patients With Actinic Keratosis
• Prolonged Use Of HRT Increases Incidence Of Lung Cancer By About 50 Percent: New Study
• pSivida Reports Presentation Of Additional Positive 24-Month Data From Iluvien(R) Phase 3 FAME™ Study For Diabetic Macular Edema At Angiogenesis
• Second Dose Of Gene Therapy For Inherited Blindness Proves Safe In Animal Study